Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 3Phase 2/3 2Phase 1/2 2Phase NA 1Phase 4 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Plasma cell 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1Immunoglobulin Light-chain Amyloidosis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Immunoglobulins, Intravenous × Clear all
NCT06064279 2024-09-19

HAITEN-ICI

VA Office of Research and Development

Phase 1/2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00547365 2013-09-19

Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction

University of Tennessee

Phase 1/2 Completed
10 enrolled 4 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡